Home › Kanser sa Tiyan › Utah
Pag-aaral pangklinika para sa Kanser sa Tiyan sa Utah
14 pag-aaral para sa Kanser sa Tiyan ang naghahanap ng mga kalahok sa mga site sa Utah.
Mga Lungsod sa Utah
Opisyal na teksto ng pag-aaral (English)
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Intermountain Health, Salt Lake City
Nagre-recruitPhase 1
Edad 19 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06586957Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT05267626A Phase 1/1b Study of IAM1363 in HER2 Cancers
- START Mountain Region, West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06253871A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- START Mountain Region, West Valley City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07070232A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT06242470A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Utah Cancer Specialists, Salt Lake City
- University of Utah Health Huntsman Cancer Hospital, Salt Lake City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT03526835A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- START Mountain Region, West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT05208762A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- START Mountain Region, Salt Lake City
- South Texas Accelerated Research Therapeutics Mountain Region, West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT06131840A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- START Mountain Region, LLC., West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 15, 2026 · NCT06657144Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Start Mountain Region /ID# 276270, West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT05005403Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- START Mountain Region, West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 10, 2026 · NCT07517198Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 30, 2026 · NCT05297734A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- START Center for Cancer Care - Mountain Region, Salt Lake City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 27, 2026 · NCT06395519SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.